CompletedNot Applicable

Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction

United States47 participantsStarted 2017-02-06

Plain-language summary

SUMMARY: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive age women with a prevalence as high as 15%. The clinical symptoms of PCOS including menstrual dysfunction, infertility, hirsutism, alopecia, acne, and the possible increased risk of diabetes and cardiovascular disease have been reported to be significant contributors to psychological morbidity and impact health-related quality of life. For women with PCOS, the changes in physical appearance and the associated mood disorders appear to be deleterious for sexual function. Vitamin D deficiency (\<20 ng/ml serum concentration of 25\[OH\]D), which affects from 67% to 85% of women,4 is closely linked to symptoms of PCOS. The main physiologic role of vitamin D is to regulate calcium and phosphorus homeostasis and to promote bone health. Although there has been an increase in awareness of the importance of sexual dysfunction and QoL in women with PCOS, few studies have evaluated the outcomes of treatment for PCOS upon sexual and subjective health status of women. The goals of this study are: 1. To evaluate the prevalence of sexual dysfunction (SDy) in women with Polycystic Ovarian Syndrome (PCOS) 2. To determine the effects of Vitamin D therapy, with and without hormonal contraceptives, on SDy in women with PCOS in the absence of depression. METHODS: The study will enroll 60 women diagnosed with PCOS and reporting SDy at the Wright State Physicians (WSP) OB-GYN Practice and the WSP Family Medicine Practice. All participants will take vitamin D 600IU/day and will choose between hormonal and non-hormonal contraceptive methods (target of 30 participants in each group). Participants will complete three study visits (Initial, Month 3, and Month 6). Vitamin D levels will be drawn at the beginning of the study and again at 3 and 6 months after initiation of vitamin D therapy. Each participant will be asked to complete the Female Sexual Function Index (FSFI) and the Beck Depression Inventory (BDI) prior to initiation of treatment and again at 6 months.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1\. Reproductive age * 2\. Have diagnosis of polycystic ovary syndrome by Rotterdam criteria (at least 2 of 3 criteria): * a. Oligomenorrhea (cycles lasting \> 35 days) or amenorrhea (\< 3 cycles in last 6 months) * b. Clinical signs of hyperandrogenism or elevated total testosterone level * c. Polycystic appearing ovaries * 3\. Report sexual dysfunction * 4\. Have no evidence of depression Exclusion Criteria: * 1\. Has chronic medical illness such as diabetes mellitus, hypertension, and previous venous embolism * 2\. Taking any prescription medications for at least 3 months prior to entry into the study with the exception of allergy or occasional pain medications * 3\. Has other etiologies of anovulation and hyperandrogenism, e.g., Cushings disease, thyroid dysfunction, elevated prolactin levels, sighs of congenital adrenal hyperplasia * 4\. Has any contraindications to hormonal contraception

What they're measuring

Sexual Function

Timeframe: Month 6

Trial details

NCT IDNCT02865187

SponsorWright State University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-03-31

Results submitted2020-07-28